Rekha Hemrajani, M.B.A.
Ms. Hemrajani has served as a member of our board of directors since May 2019. She has more than 20 years of biopharmaceutical industry experience leading operations, corporate strategy, business development, and finance functions. She is currently the chief executive officer and director of Jiya Acquisition Corporation. Previously, she served as president and chief executive officer of Aravive, Inc., chief operating officer and chief financial officer of Arcus Biosciences, chief operating officer of FLX Bio, Inc. (now RAPT Therapeutics, Inc.), and chief financial officer and senior vice president of business and financial operations at 3-V Biosciences, Inc. (now Sagimet Biosciences, Inc.). Ms. Hemrajani was also vice president, head of licensing and M&A at Onyx Pharmaceuticals (acquired by Amgen) and vice president of business development at Exelixis. She started her career in healthcare investment banking at Credit Suisse First Boston and Lehman Brothers. Ms. Hemrajani currently serves as a director for Adverum Biotechnologies, Jiya Acquisition Corporation, and ALX Oncology, Inc. and previously served as a director at Aravive. She holds a B.S. in Economics and Computer Science from the University of Michigan and an M.B.A. from the Kellogg Graduate School of Management at Northwestern University.